texas oncology more breakthroughs. more victories

Presbyterian Cancer Center Dallas Research and Clinical Trials

Texas Oncology-Presbyterian Cancer Center Dallas participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Texas Oncology-Presbyterian Cancer Center Dallas (Expand)

Biliary Cancer

STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308)

A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308) Read Moreabout STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308)

Phase: III

Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC)

An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302) Read Moreabout Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC)

Phase: III

STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma

TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements Read Moreabout STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma

Phase: II

Breast Cancer

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer

A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201) Read Moreabout Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer

Phase: II

Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)

A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301) Read Moreabout Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)

Phase: III

ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer

A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303) Read Moreabout ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer

Phase: III

Ph2 clinical trial of BNT327 in combo with treatment in breast cancer

A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02) Read Moreabout Ph2 clinical trial of BNT327 in combo with treatment in breast cancer

Phase: II

Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)

A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001) Read Moreabout Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)

Phase: III

Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)

A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001) Read Moreabout Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)

Phase: III

Ph3 HER2/neu BC (FLAMINGO-01)

A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01) Read Moreabout Ph3 HER2/neu BC (FLAMINGO-01)

Phase: III

Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer

An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010) Read Moreabout Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer

Phase: II

Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001) Read Moreabout Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Phase: III

Ph3 study of standard endocrine therapy with breast cancer

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422) Read Moreabout Ph3 study of standard endocrine therapy with breast cancer

Phase: III

Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)

EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH) Read Moreabout Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)

Phase: III

FLEX Registry: Evaluate New Gene Express

MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read Moreabout FLEX Registry: Evaluate New Gene Express

Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study)

Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT) Read Moreabout Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study)

Phase: III

Cervical Cancer

GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer

A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00) Read Moreabout GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer

Phase: III

Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE)

Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002) Read Moreabout Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE)

Phase: III

Colon Cancer

Ph3 study of FOLFIRI in participants with metastatic colorectal cancer

A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002) Read Moreabout Ph3 study of FOLFIRI in participants with metastatic colorectal cancer

Phase: III

Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)

SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) Read Moreabout Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)

Phase: III

Endometrial Cancer

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082) Read Moreabout Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

Phase: I/II

Ph3 study of GOG-3104 with endometrial cancer

A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769) Read Moreabout Ph3 study of GOG-3104 with endometrial cancer

Phase: III

Fallopian Tube Cancer

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Gastric Cancer

A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Phase: II

Head and Neck Cancer

A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Phase: II

STAR Ph3 study to evaluate to treat patients with HNSCC

A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02) Read Moreabout STAR Ph3 study to evaluate to treat patients with HNSCC

Phase: III

Ph3 study of pembro in HNSCC in the disease without curative therapy available

A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03) Read Moreabout Ph3 study of pembro in HNSCC in the disease without curative therapy available

Phase: III

Lung Cancer

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC

A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153) Read Moreabout Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC

Phase: II

Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237)

A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201) Read Moreabout Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237)

Phase: II

Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC

A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005) Read Moreabout Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC

Phase: II

Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17)

A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017) Read Moreabout Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17)

Phase: II

Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS)

A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012) Read Moreabout Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS)

Phase: II

Ph3 Tarlatamab in combo with Durvalumab ES-SCLC

A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041) Read Moreabout Ph3 Tarlatamab in combo with Durvalumab ES-SCLC

Phase: III

STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC

A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217) Read Moreabout STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC

Phase: III

STAR: PH1/3 Biomarker unresectable stg3 NSCLC

A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777) Read Moreabout STAR: PH1/3 Biomarker unresectable stg3 NSCLC

Phase: III

Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)

A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003) Read Moreabout Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)

Phase: III

Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4)

A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721) Read Moreabout Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4)

Phase: II/III

Lymphomas

Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma

A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145) Read Moreabout Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma

Phase: III

Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3)

A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202] Read Moreabout Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3)

Phase: II

Melanoma

Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma

A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122) Read Moreabout Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma

Phase: III

Myelofibrosis

A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS

Phase: I/III

Ovarian Cancer

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082) Read Moreabout Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

Phase: I/II

Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6)

A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002) Read Moreabout Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6)

Phase: II

Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)

A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301) Read Moreabout Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)

Phase: III

Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer

A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02) Read Moreabout Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer

Phase: III

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Pancreatic Cancer

Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC)

A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302) Read Moreabout Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC)

Phase: III

Peritoneal Cancer

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Rectal Cancer

Ph3 study of FOLFIRI in participants with metastatic colorectal cancer

A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002) Read Moreabout Ph3 study of FOLFIRI in participants with metastatic colorectal cancer

Phase: III

Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)

SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) Read Moreabout Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)

Phase: III

Solid Tumors

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read Moreabout STAR Ph1/2 MRTX849 Solids KRAS G12C

Phase: I/II

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01) Read Moreabout STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors

Phase: IV

EAP for AGEN2034 either monotherapy or as used in combo with zalifrelimab

Expanded Access for Cancer Treatment with Balstilimab (AGEN2034) either as Monotherapy or as used in Combination with Zalifrelimab (AGEN1884) Read Moreabout EAP for AGEN2034 either monotherapy or as used in combo with zalifrelimab

Phase: II

Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001) Read Moreabout Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase: I/II

Urothelial Cancer

Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082) Read Moreabout Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

Phase: I/II